Yamada, Y., Denda, T., Gamoh, M., Iwanaga, I., Yuki, S., Shimodaira, H., . . . Ishioka, C. (2018). S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): A randomized, open-label, phase III, noninferiority trial. Ann Oncol.
Citação norma ChicagoYamada, Y., et al. "S-1 and Irinotecan Plus Bevacizumab Versus MFOLFOX6 or CapeOX Plus Bevacizumab As First-line Treatment in Patients With Metastatic Colorectal Cancer (TRICOLORE): A Randomized, Open-label, Phase III, Noninferiority Trial." Ann Oncol 2018.
MLA引文Yamada, Y., et al. "S-1 and Irinotecan Plus Bevacizumab Versus MFOLFOX6 or CapeOX Plus Bevacizumab As First-line Treatment in Patients With Metastatic Colorectal Cancer (TRICOLORE): A Randomized, Open-label, Phase III, Noninferiority Trial." Ann Oncol 2018.